Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual disease (MRD) following treatment for solid tumors predicts relapse. These results suggest that ctDNA MRD could identify candidates for adjuvant therapy and measure response to such treatment. Importantly, factors such as assay type, amount of ctDNA release, and technical and biological background can affect ctDNA MRD results. Furthermore, the clinical utility of ctDNA MRD for treatment personalization remains to be fully established. Here, we review the evidence supporting the value of ctDNA MRD in solid cancers and highlight key considerations in the application of this potentially transformative biomarker. Significance: ctDNA analysis enables detection of MRD and predicts relapse after definitive treatment for solid cancers, thereby promising to revolutionize personalization of adjuvant and consolidation therapies.

中文翻译：

---

检测实体瘤的液体残留物：具有最小残留疾病的循环肿瘤 DNA


越来越多的证据表明，实体瘤治疗后的循环肿瘤 DNA (ctDNA) 微小残留病 (MRD) 可预测复发。这些结果表明 ctDNA MRD 可以识别辅助治疗的候选者并测量对此类治疗的反应。重要的是，检测类型、ctDNA 释放量以及技术和生物学背景等因素可能会影响 ctDNA MRD 结果。此外，ctDNA MRD 在治疗个性化方面的临床效用仍有待充分确定。在这里，我们回顾了支持 ctDNA MRD 在实体癌中价值的证据，并强调了应用这种潜在变革性生物标志物时的关键考虑因素。意义：ctDNA 分析能够检测 MRD 并预测实体癌根治性治疗后的复发，从而有望彻底改变辅助和巩固疗法的个性化。